NCT03853317 - QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 19, 2020

Primary Completion Date

September 29, 2021

Study Completion Date

September 19, 2022

Conditions

Merkel Cell Carcinoma

Interventions

BIOLOGICAL

Avelumab

For the treatment of adults and pediatric patients 12 years and older with Metastatic Merkel Cell Carcinoma (MCC).

BIOLOGICAL

N-803

Recombinant human super agonist interleukin-15 (IL-15) complex

BIOLOGICAL

haNK™

haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).

Trial Locations (5)

33136

University of Miami, Sylvester Comprehensive Cancer Center, Miami

33176

Miami Cancer Institute - Baptist Health, Miami

44195

Cleveland Clinic Foundation, Cleveland

63110

Washington University School of Medicine in St. Louis, St Louis

94143

University of California San Francisco, San Francisco